Revolutionizing Obesity Treatment | Metsera
We are a clinical-stage biotechnology company focused on engineering, developing, manufacturing, and ultimately commercializing a new generation of potent, ultra-long acting, scalable nutrient-stimulated hormone (NuSH) therapies for obesity and related diseases.
Metsera Science | Next-Generation NuSH Therapies and Platforms
Discover Metsera’s innovative platforms: MINT, HALO, and MOMENTUM, enabling scalable, potent, and tolerable NuSH therapies for obesity and metabolic conditions.
Metsera Pipeline | Advancing Next-Gen Obesity Therapies
Explore Metsera's pipeline of innovative NuSH therapies. From oral to injectable solutions, we aim to deliver best-in-class potency, durability, and scalability for obesity treatment.
Metsera, Inc. Common Stock (MTSR) - Yahoo Finance
Find the latest Metsera, Inc. Common Stock (MTSR) stock quote, history, news and other vital information to help you with your stock trading and investing.
Metsera Announces Closing of Initial Public Offering and Full …
In addition, Metsera today announced the exercise in full by the underwriters of their option to purchase 2,291,666 additional shares, at the initial public offering price of $18.00 per share, and ...
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 · Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body weight compared to baseline at 36 days. While the biotech has yet to...
Metsera Announces Positive Topline Phase 2a Clinical Data for its …
Jan 7, 2025 · Metsera is advancing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies with potential best-in-class profiles to address multiple therapeutic targets and meet the future needs of a rapidly evolving weight loss treatment landscape.
Metsera Touts ‘Powerful’ Weight Loss Results—Again
Jan 7, 2025 · Months after posting weight loss of 7.5% at 36 days for patients taking MET-097i, Metsera releases mid-stage results of just over 11% average body weight reduction at 12 weeks, with no plateau and a promising safety profile.
Arch-backed obesity biotech launches with $290M - Fierce Biotech
Apr 18, 2024 · Clinical-stage Metsera has emerged from stealth with $290 million in hand and the bold vision of ushering in the next generation of obesity and metabolic disease medicines. “It's an almost...
Nine-month-old obesity player Metsera files an IPO
6 days ago · Metsera's co-founder, chief executive, and president Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs.